• Mashup Score: 0
    Treating cancer during the COVID-19 pandemic - 3 year(s) ago

    Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, talks on the risks of COVID-19 infections in patients with cancer,…

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Treating cancer during the #COVID19 pandemic w/ @FedericoCappuz1 of @AUSLRomagna Watch here 👉 https://t.co/tW5CrtiTpY👈 @VJOncology @myESMO @IASLC @OncoAlert #ELCC21 #LungCancer #LCsm #Oncology #OncoAlert #MedOnc #ClinOnc #NCRM21 #ResearchSavesLives #Oncology

  • Mashup Score: 0
    Update from a phase 1 study of AMG 757 in SCLC - 3 year(s) ago

    Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, shares an update on a Phase…

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Update from a phase 1 study of AMG 757 in #SCLC w/ @DrSanjayPopat of @royalmarsdenNHS Watch here 👉 https://t.co/rEWo4wPIrx👈 @VJOncology @OncoAlert @myESMO @IASLC #ELCC21 #LungCancer #LCsm #OncoAlert #MedOnc #ClinOnc #NCRM21 #ResearchSavesLives

  • Mashup Score: 1
    Management of patients with PDL1-high advanced NSCLC - 3 year(s) ago

    Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, discusses the management of patients with non-small cell lung cancer (NSCLC)…

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Management of patients with PDL1-high advanced #NSCLC w/ @FedericoCappuz1 of @AUSLRomagna Watch here 👉 https://t.co/XrJ0Kf1vVN👈 @VJOncology @myESMO @IASLC @OncoAlert #ELCC21 #LungCancer #LCsm #Oncology #OncoAlert #MedOnc #ClinOnc #NCRM21 #ResearchSavesLives

  • Mashup Score: 1
    Novel targets for NSCLC - 3 year(s) ago

    Marina Garassino, MD, University of Chicago, Chicago, IL, talks on uncommon targets for the treatment of non-small cell lung cancer…

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Novel targets for #NSCLC w/ @marinagarassino of @UChicago Watch here 👉 https://t.co/hcqPpW1vH6👈 @VJOncology @myESMO @IASLC @OncoAlert #ELCC21 #LungCancer #LCsm #OncoAlert #MedOnc #ClinOnc #NCRM21 #ResearchSavesLives

  • Mashup Score: 1
    Targeting RET in lung cancer - 3 year(s) ago

    Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, outlines therapeutic options for the treatment of patients with RET-positive lung…

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Targeting RET in lung cancer w/ @FedericoCappuz1 of @AUSLRomagna 👉https://t.co/c8T6cRquSA👈 @VJOncology @myESMO @IASLC @OncoAlert #ELCC21 #LungCancer #LCsm #NSCLC #SCLC #Mesothelioma #Oncology #OncoAlert #MedOnc #ClinOnc

  • Mashup Score: 2
    VJOncology – The video journal of oncology - 3 year(s) ago

    The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      Didn’t have time to attend #ELCC21? Catch up here 👉https://t.co/fXIIknvKWs👈 It was an amazing showcase and we had a fantastic time talking to experts! 👨‍⚕‍👩‍⚕‍ @VJOncology @myESMO @IASLC @OncoAlert #LungCancer #LCsm #NSCLC #SCLC #Mesothelioma #Oncology #OncoAlert https://t.co/JLY1RLOVMf

  • Mashup Score: 0
    AMG 757 Shows Early Efficacy, Safety in Small Cell Lung Cancer - 3 year(s) ago

    The half-life extended, DLL3-targeting bispecific T-cell engager AMG 757 demonstrated early signals of efficacy and a favorable safety profile in patients with small cell lung cancer.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      The half-life extended, DLL3-targeting bispecific T-cell engager AMG 757 demonstrated early signals of efficacy and a favorable safety profile in patients with small cell lung cancer. @fblackhall @myESMO #ELCC21 #lcsm https://t.co/rypKb381vR

Load More